Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact

Annals of Surgery

Volumn 259, Issue 2, 2014, Pages 336-345

  Utsunomiya, Tohru ^a   Shimada, Mitsuo ^a   Kudo, Masatoshi ^b   Ichida, Takafumi ^c   Matsui, Osamu ^d   Izumi, Namiki ^e   Matsuyama, Yutaka ^f   Sakamoto, Michiie ^g   Nakashima, Osamu ^h   Ku, Yonson ⁱ   Kokudo, Norihiro ^j   Makuuchi, Masatoshi ^k  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^d KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^e MUSASHINO RED CROSS HOSPITAL   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KURUME UNIVERSITY HOSPITAL   (Japan)

ⁱ KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j UNIVERSITY OF TOKYO   (Japan)

^k JAPANESE RED CROSS MEDICAL CENTER   (Japan)

more..

Author keywords

hepatectomy; nationwide survey; non B non C; prognostic factor; radiofrequency ablation; transarterial chemoembolization

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BILIRUBIN; DECARBOXYPROTHROMBIN; INDOCYANINE GREEN; PROTHROMBIN;

ADULT; ADVANCED CANCER; AGE; AGED; ALBUMIN BLOOD LEVEL; ALCOHOL CONSUMPTION; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COHORT ANALYSIS; DISEASE SEVERITY; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; JAPAN INTEGRATED STAGING SCORE; LIVER CELL CARCINOMA; LIVER INJURY; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PORTAL VEIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; SCORING SYSTEM; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR INVASION; VASCULAR TUMOR; VERY ELDERLY;

EID: 84892926926     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31829291e9     Document Type: Article

References (37)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750.
4. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485-1491.
5. Ikai I, Arii S, OkazakiM, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007;37:676-691.
6. Namiki I, Nishiguchi S, Hino K, et al. Management of hepatitis C: report of the consensus meeting at the 45th annual meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:347-368.
7. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res. 2007;37(suppl 2):S95-S100.
8. Tanaka H, Imai Y, Hiramatsu N, et al. Declining incidence of hepatocellular carcinoma inOsaka, Japan, from 1990 to 2003.Ann InternMed. 2008;148:820-826.
9. Utsunomiya T, Shimada M. Molecular characteristics of non-cancerous liver tissue in non-B non-C hepatocellular carcinoma. Hepatol Res. 2011;41:711-721.
10. Nagaoki Y, Hyogo H, Aikata H, et al. Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res. 2012;42:368-375.
11. Hatanaka K, Kudo M, Fukunaga T, et al. Clinical characteristics of NonB NonC-HCC: comparison with HBV and HCV related HCC. Intervirology. 2007;50:24-31.
12. Abe H, Yoshizawa K, Kitahara T, et al. Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. J Gastroenterol. 2008;43:967-974.
13. Ikeda K, Kobayashi M, Someya T, et al. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat. 2009;16:437-443.
14. Shinkawa H, Uenishi T, Takemura S, et al. Risk factors for postoperative recurrence of non-B non-C hepatocellular carcinoma. JHepatobiliary Pancreat Sci. 2010;17:291-295.
15. Kim SK, Marusawa H, Eso Y, et al. Clinical characteristics of non-B non-C hepatocellular carcinoma: a single-center retrospective study. Digestion. 2011;84(suppl 1):43-49.
16. Nakajima T, Nakashima T, Yamaoka J, et al. Greater age and hepatocellular aging are independent risk factors for hepatocellular carcinoma arising from non-B non-C non-Alcoholic chronic liver disease. Pathol Int. 2011;61:572-576.
17. Chok KS, Ng KK, Poon RT, et al. Comparable survival in patients with unresectable hepatocellular carcinoma treated by radiofrequency ablation or transarterial chemoembolization. Arch Surg. 2006;141:1231-1236.
18. Hasegawa K, Makuuchi M, Takayama T, et al. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol. 2008;49:589-594.
19. Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252:903-912.
20. Cho YK, Kim JK, KimWT, et al. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: aMarkov model analysis. Hepatology. 2010;51:1284-1290.
21. Luo J, Peng ZW, Guo RP, et al. Hepatic resection versus transarterial lipiodol chemoembolization as the initial treatment for large, multiple, and resectable hepatocellular carcinomas: a prospective nonrandomized analysis. Radiology. 2011;259:286-295.
22. Makuuchi M, Kokudo N, Arii S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2008;38:37-51.
23. The Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 2nd English ed. Tokyo, Japan: Kanehara & Co, Ltd; 2003.
24. Kudo M, Chung H, Haji S, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004;40:1396-1405.
25. Schneider HJ, Wallaschofski H, V̈olzke H, et al. Incremental effects of endocrine and metabolic biomarkers and abdominal obesity on cardiovascular mortality prediction. PLoS One. 2012;7:e33084.
26. Alisi A, Ghidinelli M, Zerbini A, et al. Hepatitis C virus and alcohol: same mitotic targets but different signaling pathways. J Hepatol. 2011;54:956-963.
27. Takayasu K, Arii S,Kudo M, et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol. 2012;56:886-892.
28. Utsunomiya T, Shimada M, Imura S, et al. Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J Gastroenterol. 2010;45:146-152.
29. Wakai T, Shirai Y, Yokoyama N, et al. Hepatitis viral status affects the pattern of intrahepatic recurrence after resection for hepatocellular carcinoma. Eur J Surg Oncol. 2003;29:266-271.
30. Kondo K, Chijiiwa K, Funagayama M, et al. Differences in long-term outcome and prognostic factors according to viral status in patients with hepatocellular carcinoma treated by surgery. J Gastrointest Surg. 2008;12:468-476.
31. Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009;49:851-859.
32. Reddy SK, Steel JL, Chen HW, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology. 2012;55:1809-1819.
33. Okanoue T, Umemura A, Yasui K, et al. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. J Gastroenterol Hepatol. 2011;26:153-162.
34. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-1428.
35. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer. 2009;115:5651-5661.
36. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51:1820-1832.
37. Minagawa M, Ikai I, Matsuyama Y, et al. Staging of hepatocellular carcinoma assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245:909-922.